HCA vs LH
HCA Healthcare, Inc. and Labcorp Holdings Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | HCA | LH |
|---|---|---|
| Revenue | $75.6B | $14.0B |
| Net income | $6.8B | $876.5M |
| Gross margin | · | 28.8% |
| Net margin | 10.3% | 6.3% |
| Return on equity | · | 10.5% |
| Diluted EPS | $28.33 | $10.46 |
| Dividend / share | $2.88 | $2.88 |
| Payout ratio | 10.0% | 27.5% |
| Free cash flow | $7.7B | $1.2B |
| Equity | $-6.0B | $8.6B |
| Net debt / equity | · | 0.59× |
| Current ratio | 0.97× | 1.42× |
| Revenue CAGR 5y | 8.0% | −0.0% |
| Profit CAGR 5y | 12.6% | −10.8% |
HCA bills 5.4× the revenue of LH, and keeps more of each dollar of revenue as profit (10.3% against 6.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | HCA | LH |
|---|---|---|
| FY2025 | $75.6B | $14.0B |
| FY2024 | $70.6B | $13.0B |
| FY2023 | $65.0B | $12.2B |
| FY2022 | $60.2B | $11.9B |
| FY2021 | $58.8B | $13.1B |
| FY2020 | $51.5B | $14.0B |
| FY2019 | $51.3B | $11.6B |
| FY2018 | $46.7B | $11.3B |
| FY2017 | $43.6B | $10.3B |
| FY2016 | $41.5B | $9.6B |
Bottom line
| Fiscal year | HCA | LH |
|---|---|---|
| FY2025 | $6.8B | $876.5M |
| FY2024 | $5.8B | $746.0M |
| FY2023 | $5.2B | $418.0M |
| FY2022 | $5.6B | $1.3B |
| FY2021 | $7.0B | $2.4B |
| FY2020 | $3.8B | $1.6B |
| FY2019 | $3.5B | $823.8M |
| FY2018 | $3.8B | $883.7M |
| FY2017 | $2.2B | $1.2B |
| FY2016 | $2.9B | $711.8M |
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$61,648,300,000 | HCA |
| FY2024 | +$57,594,100,000 | HCA |
| FY2023 | +$52,806,400,000 | HCA |
| FY2022 | +$48,369,100,000 | HCA |
| FY2021 | +$45,615,900,000 | HCA |
| FY2020 | +$37,554,500,000 | HCA |
| FY2019 | +$39,781,200,000 | HCA |
| FY2018 | +$35,343,600,000 | HCA |
| FY2017 | +$33,306,000,000 | HCA |
| FY2016 | +$31,937,100,000 | HCA |
| FY2014 | +$30,906,400,000 | HCA |
| FY2013 | +$28,373,700,000 | HCA |
| FY2012 | +$27,341,600,000 | HCA |
| FY2011 | +$24,139,700,000 | HCA |
| FY2010 | +$23,031,100,000 | HCA |
| FY2009 | +$22,081,300,000 | HCA |
HCA has reported the higher revenue in every one of these 16 fiscal years. The gap has widened since the earliest year compared.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +4.0 pp | HCA |
| FY2024 | +3.7 pp | HCA |
| FY2023 | +5.9 pp | HCA |
| FY2022 | +0.6 pp | HCA |
| FY2021 | −5.0 pp | LH |
| FY2020 | −2.6 pp | LH |
| FY2019 | +0.9 pp | HCA |
| FY2018 | +1.6 pp | HCA |
| FY2017 | −5.7 pp | LH |
| FY2016 | +0.8 pp | HCA |
| FY2014 | −2.1 pp | LH |
| FY2013 | −4.1 pp | LH |
| FY2012 | −4.2 pp | LH |
| FY2011 | −0.0 pp | LH |
| FY2010 | −5.8 pp | LH |
| FY2009 | −6.7 pp | LH |
The higher net margin has changed hands between HCA and LH over this period.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LH's net margin has been more volatile than HCA's over the 16 comparable fiscal years — 3.3 percentage points of standard deviation against 2.2.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between HCA and LH over these 16 fiscal years — HCA led in 7 and LH in 9.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.